Innovus Pharmaceuticals Reports Preliminary Q3 2018 Sales Revenue of $7.0 million to $7.1 million

Innovus Pharmaceuticals, Inc., ("Innovus Pharma”) (OTCQB: INNV), today announced preliminary third quarter 2018 net revenue is estimated to be between $7.0 million to $7.1 million or an approximate 215-219% increase from the third quarter of 2017. Innovus Pharma's third quarter 2018 anticipated revenue results are preliminary and based on the most current information available and are subject to completion of the condensed consolidated financial statements for the third quarter of 2018, which are to be filed with the SEC no later than November 14, 2018.

"We are excited that the exceptional growth in our sales channels, additional markets and product pipeline which we saw in Q2 2018 is continuing on a fairly even path in Q3 2018 with our estimated third quarter net revenue of between $7.0 million to $7.1 million. To date, for the three quarters of 2018, we currently expect to have total revenue of $18.9 million to $19.0 million, which is well on our way to achieving at least the $23 million in net revenue that we have currently projected for 2018,” stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. "We continue to work hard towards our operational and financial goals and to increase the breadth of our product offerings and achieve potential profitability for the fourth quarter.”

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to be a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.

Innovus Pharma’s Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its financial results, projected revenues, projected online subscribers and other customers, estimated markets for its products, and statements about achieving its other corporate and business development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181105005056/en/